The Phase 3 DISCREET trial demonstrates that apremilast provides sustained clinical efficacy and quality-of-life improvements for patients with moderate to severe genital psoriasis over 32 weeks, offering a viable oral alternative for a traditionally difficult-to-treat and stigmatized condition.